Opinion|Videos|November 8, 2024
Navigating Intensive Chemotherapy in the Community Setting
Author(s)Margaret T. Kasner, MD, Christian Fidler, MD
Panelists discuss how community settings face unique challenges in delivering intensive chemotherapy regimens for secondary AML, including limited resources and expertise, but can implement best practices and leverage potential benefits of community-based care to provide effective treatment.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- In the community setting, what are some of the unique challenges faced in delivering intensive chemotherapy regimens?
- What are best practices you/your practice have implemented to mitigate these challenges?
- Please describe some of the potential benefits of treating a patient in the community setting or in the outpatient setting with intensive induction (e.g., CPX-351).
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.
Data from EXCALIBER-RRMM supported FDA accelerated approval of iberdomide plus daratumumab/dexamethasone in R/R multiple myeloma.
The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.
Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR-TKI-pretreated advanced clear cell renal cell carcinoma.
A new study suggests genomic newborn screening could identify children at risk for early cancers and enable earlier diagnosis and less toxic treatment.
The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
3
Five Under 5: Top Oncology Videos for the Week of 8/9
4
Zipalertinib Plus Chemotherapy Improves PFS in First-Line EGFR Exon 20 Insertion+ NSCLC
5